Clindamycin Dosing Recommendations
For adults with serious infections, use clindamycin 150-300 mg every 6 hours orally or 600-900 mg every 8 hours IV; for more severe infections, increase to 300-450 mg every 6 hours orally or 900 mg every 8 hours IV, with no dose adjustment needed for renal disease but caution required in severe liver disease. 1
Adult Dosing
Oral Administration
- Serious infections: 150-300 mg every 6 hours
- Severe infections: 300-450 mg every 6 hours
- Must be taken with a full glass of water to prevent esophageal irritation 1
Intravenous Administration
- Standard dosing: 600 mg every 8 hours 2
- Severe infections: 900 mg every 8 hours 2
- For necrotizing infections (streptococcal): 600-900 mg every 8 hours IV plus penicillin 2
- For clostridial myonecrosis: 600-900 mg every 8 hours IV plus penicillin 2
A meta-analysis demonstrated significantly higher cure rates with 900 mg every 8 hours (90.5%) versus 600 mg every 8 hours (75.6%) for intraabdominal infections (p=0.03), suggesting patient-specific dosing with higher doses for more severe presentations. 3
Pediatric Dosing (Beyond Neonatal Period)
For Children Who Can Swallow Capsules
- Serious infections: 8-16 mg/kg/day divided into 3-4 equal doses
- Severe infections: 16-20 mg/kg/day divided into 3-4 equal doses 1
Intravenous Dosing
- Standard: 10-13 mg/kg/dose every 8 hours 2
- For necrotizing infections: 10-13 mg/kg/dose every 8 hours 2
Dose based on total body weight regardless of obesity 1
Recent evidence suggests that 30 mg/kg/day oral dosing may be effective for pediatric musculoskeletal infections in MRSA-prevalent communities, though current guidelines recommend approximately 40 mg/kg/day for MRSA infections. 4 The lower dose showed no significant difference in readmission rates, with illness severity being a more important predictor of outcomes than antibiotic dosing.
Liver Disease Adjustments
In patients with moderate to severe liver disease, dosage modification may not be necessary when dosing every 8 hours, as accumulation rarely occurs with this interval, though periodic liver enzyme monitoring is essential. 1
Key Considerations:
- Clindamycin half-life is prolonged in liver disease 1, 5, 6
- Studies show 5-hour serum levels are approximately 3 times higher in patients with moderate-to-severe hepatic dysfunction (24.3 mcg/mL) versus normal liver function (8.3 mcg/mL) 6
- Despite prolonged half-life, every 8-hour dosing prevents significant accumulation 1, 5
- Monitor liver enzymes periodically during treatment 1
- No evidence that clindamycin exacerbates preexisting hepatic dysfunction 5
Critical Drug Interaction: Rifampicin
When clindamycin is combined with rifampicin, oral administration is contraindicated due to dramatically reduced bioavailability; use IV dosing of at least 3600-4800 mg/day, preferably by continuous infusion. 7
Rifampicin increases clindamycin clearance by 3-fold and reduces oral bioavailability from 56% to as low as 4% depending on rifampicin dose. 7 This combination requires:
- Minimum 3600 mg/day IV for most pathogens
- 4800 mg/day for MIC at 0.25 mg/L (EUCAST breakpoint for S. aureus)
- Continuous infusion superior to intermittent dosing every 6-8 hours
Important Precautions
- No renal dose adjustment required 1
- Use with caution in patients with gastrointestinal disease, particularly colitis 1
- Monitor for C. difficile-associated diarrhea; discontinue if significant diarrhea occurs 1
- For β-hemolytic streptococcal infections, continue treatment for at least 10 days 1
- Clindamycin has neuromuscular blocking properties; use cautiously with other neuromuscular blocking agents 1
- CYP3A4 inhibitors may increase clindamycin levels; CYP3A4 inducers may decrease levels 1